RECHEM
Welcome to our website!|Hot Line: 86-21-31433387|E-mail: sales@rechemscience.com
Products Category
Contact Us
| Tel: | +86-21-31433387 |
| +86-15618786686 | |
| Email: | sales@rechemscience.com |
| info@rechemscience.com | |
| QQ: | 1369748377 |
| Skype: | sales@rechemscience.com |
Home > Products
| Cat.No. | Product name | Product Description |
| R2033283 | Danicopan (ACH-4471) | Danicopan (ACH-4471), a selective and orally active small-molecule factor D |
| R2033226 | AP3 Intermidate 1 | Ansamitocin P-3 (Antibiotic C 15003P3) is a microtubule inhibitor. Ansamitocin P |
| R2033227 | AP3 Impurity 1 | Ansamitocin P-3 (Antibiotic C 15003P3) is a microtubule inhibitor. Ansamitocin P |
| R2033230 | DM1 Impurity 4 | Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable may |
| R2033231 | DM4 | DM4 is is an antitubulin agent that inhibit cell division. DM4 can be used in th |
| R2033234 | Lys-SMCC-DM1 | Lys-SMCC-DM1 is the active metabolite of DM1. DM1 is a tubulin inhibitor. |
| R2033235 | PK11007 | PK11007 is a mild thiol alkylator with anticancer activity. PK11007 stabilizes p |
| R2033236 | Tetrahydrobiopterin | Tetrahydrobiopterin is a cofactor of the aromatic amino acid hydroxylases enzyme |
| R2033237 | Pembrolimumab | Pembrolizumab is a humanized antibody inhibiting the programmed cell death 1 (PD |
| R2033238 | Nivolumab(BMS-936558;ONO-4538;MDX-1106) | Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody to treat adv |
| R2033239 | Trastuzumab | Trastuzumab is a humanized monoclonal antibody for patients with invasive breast |
| R2033240 | Aflibercept | Aflibercept is used to treat wet age-related macular degeneration (AMD; an ongoi |
| R2033241 | Cetuximab | Cetuximab is a monoclonal antibody that inhibits epidermal growth factor recepto |
| R2033242 | Adalimumab | Adalimumab is a human monoclonal IgG1 antibody targeting tumour necrosis factor |
| R2033243 | Infliximab | Infliximab is a humanized antibody against tumor necrosis factor α (TNF-α) that |
| R2033244 | Rituximab | Rituximab is an anti-CD20 chimeric monoclonal antibody used to treat certain aut |
| R2033245 | Ipilimumab;MDX-010;BMS-734016 | Ipilimumab is a fully human monoclonal IgG1κ antibody against the cytotoxic T-ly |
| R2033246 | Vedolizumab | Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin fo |
| R2033247 | Denosumab | Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast |
| R2033248 | Evolocumab | Evolocumab is a human IgG2 monoclonal antibody that binds to human PCSK9 (Propro |
| R2033249 | Alirocumab | Alirocumab is a human monoclonal antibody that inhibits PCSK9. It is produced by |
| R2033250 | Eculizumab | Eculizumab is a recombinant humanized monoclonal antibody against the complement |
| R2033251 | Ustekinumab | Ustekinumab is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody. |
| R2033252 | Omalizumab | Omalizumab is a recombinant, humanized, monoclonal antibody against human immuno |
| R2033253 | Ramucirumab | Ramucirumab is a human VEGFR-2 antagonist for the treatment of solid tumors. Ram |
